Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities<\/i><\/p>\n
\nBARCELONA, Spain \u2014 2 Sept. 2025 \u2014<\/strong> ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced more than 450 companies, including 19 of the top 20 biopharmas, have adopted ³Ô¹Ï±¬ÁÏ RIM<\/a> for regulatory information management (RIM) on a unified platform. Continued innovation to advance connectivity now includes partnerships with Accumulus Technologies<\/a> and DNAnexus<\/a>, enabling integration with multi-health authority platforms to drive efficiency and compliance.\n<\/p>\n \n\u201cRegulatory teams are adopting new ³Ô¹Ï±¬ÁÏ product innovations to continually improve efficiency and reduce cycle times. Strengthened by industry partnerships, ³Ô¹Ï±¬ÁÏ RIM provides an end-to-end solution that accelerates time to market, improves global stakeholder collaboration, and enables seamless data flow in a rapidly evolving regulatory environment,\u201d said Marc Gabriel, vice president, regulatory at ³Ô¹Ï±¬ÁÏ.\n<\/p>\n \nCompanies using ³Ô¹Ï±¬ÁÏ RIM applications can streamline processes across all steps of the regulatory lifecycle. With ³Ô¹Ï±¬ÁÏ Submissions Publishing<\/a>, more than 85 organizations are using continuous publishing to reduce rework and remove bottlenecks, accelerating submission timelines.\n<\/p>\n \n\u201cOur strategic partnership will connect the Accumulus platform and ³Ô¹Ï±¬ÁÏ RIM for greater interoperability to modernize how information is instantly and simultaneously shared with our growing network of over 70 regulatory agencies worldwide. By facilitating seamless regulatory submissions, we can empower our mutual customers to get treatments to patients faster,\u201d said Francisco Nogueira, CEO of Accumulus Technologies.\n<\/p>\n \n\u201cIntegrating DNAnexus Trusted Regulatory Spaces (TRS) and ³Ô¹Ï±¬ÁÏ RIM will provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals,\u201d said Thomas Laur, CEO of DNAnexus.\n<\/p>\n \n³Ô¹Ï±¬ÁÏ RIM streamlines global regulatory processes on a single, cloud-based platform. It is part of ³Ô¹Ï±¬ÁÏ Development Cloud<\/a>, the technology foundation for product development across clinical, quality, regulatory, and safety. To learn more about ³Ô¹Ï±¬ÁÏ RIM, visit veeva.com\/eu\/RIM<\/a>.\n<\/p>\n \nAbout ³Ô¹Ï±¬ÁÏ Systems<\/strong> \n³Ô¹Ï±¬ÁÏ Forward-Looking Statements<\/strong> ###<\/center><\/p>\n
\n³Ô¹Ï±¬ÁÏ delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,500 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.\n<\/p>\n
\nThis release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.\n<\/p>\n